Neuroprotective Research Peptides

18 research peptides demonstrate neuroprotective properties. This collection covers their mechanisms, evidence base, and research applications.

BPC-157 is a synthetic peptide composed of 15 amino acids, derived from a protein found in human gastric juice. It has garnered attention for its regenerative and cytoprotective properties, evidenced by numerous animal studies that demonstrate its efficacy in promoting healing across various tissues, including tendons, ligaments, muscles, and nerves. Despite this extensive preclinical support, human clinical data remain sparse, with only three small pilot studies exploring its effects in conditions such as knee pain and interstitial cystitis. Regulatory status is notable, as the FDA classifies it as Category 2, while WADA prohibits its use in competitive sports. Mechanistically, BPC-157 promotes angiogenesis, reduces inflammation, and enhances growth factor signaling, yet its rapid metabolism and limited bioavailability in humans pose challenges for therapeutic application.

GHRP-6, a synthetic hexapeptide, serves as a potent growth hormone secretagogue by activating the ghrelin receptor (GHS-R1a). It is recognized not only for its role in stimulating growth hormone release but also for its cytoprotective properties, which have been observed in preclinical models. Research indicates its ability to mitigate oxidative stress and inflammation through interactions with the CD36 receptor, thereby offering potential neuroprotective benefits. The peptide's mechanism involves pulsatile GH release and subsequent elevation of IGF-1 levels without disrupting physiological feedback mechanisms. Despite its promising preclinical findings, the lack of extensive human trials limits the understanding of its full therapeutic potential and safety profile. Current data suggest a half-life of approximately 2.5 hours, indicating that further investigation is warranted to explore its applications in neuroprotection and beyond.

Selank is a synthetic heptapeptide designed as a structural analogue of tuftsin, which is known for its immunomodulatory properties. Approved in Russia as an anxiolytic and nootropic, Selank has demonstrated the ability to cross the blood-brain barrier, thereby influencing GABAergic neurotransmission and modulating stress-related neuropeptides. Research involving patients with generalized anxiety disorder (GAD) has shown that Selank can effectively reduce anxiety levels comparable to traditional anxiolytics, but without the associated risks of sedation or dependency. Its mechanism includes enhancing GABA receptor activity and increasing the expression of specific neuropeptides, which may contribute to its cognitive-enhancing effects. While promising, the clinical application of Selank outside of Russia remains limited, and more comprehensive studies are needed to fully understand its neuroprotective capabilities and long-term safety.

Semax, a heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH), has been extensively studied for its neuroprotective and cognitive-enhancing properties. Approved in Russia and Ukraine for various neurological conditions, Semax functions by selectively influencing brain pathways without activating adrenal corticosteroid production. Its mechanism involves increasing brain-derived neurotrophic factor (BDNF) levels, which support neuroplasticity and cognitive function. Research indicates that Semax can enhance nerve growth factor (NGF) levels and modulate neurotransmitter systems, suggesting a multifaceted role in neuroprotection. Notably, recent studies have explored its potential in managing conditions such as Alzheimer's disease, where it may influence amyloid-beta aggregation. Despite its established use in certain regions, further clinical trials are necessary to validate its efficacy and safety across broader populations.

Dihexa (PNB-0408) is a synthetic small molecule derived from angiotensin IV that has shown promise in promoting synaptogenesis and neuroplasticity through its action as a hepatocyte growth factor (HGF) mimetic. Developed at Washington State University, Dihexa activates the HGF/c-Met signaling pathway, which is crucial for neuronal survival and cognitive function. Preclinical studies in models of Alzheimer's disease have demonstrated its ability to enhance cognitive performance while reducing neuroinflammation. Importantly, Dihexa exhibits good oral bioavailability and can cross the blood-brain barrier, which is a significant advantage over larger HGF proteins. However, the absence of human clinical trials limits its therapeutic applicability and safety assessment. Future research is needed to explore its potential in both neurodegenerative diseases and peripheral nerve regeneration.

Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide first isolated from rabbit brains in 1977. Its name reflects its ability to induce delta wave patterns in EEG recordings, suggesting a role in sleep regulation. Research indicates that DSIP interacts with various neuroendocrine pathways, including the GABAergic and glutamatergic systems, as well as modulating the hypothalamic-pituitary-adrenal (HPA) axis. While human studies have yielded mixed results regarding its efficacy in sleep disorders, some European trials indicate potential benefits for insomnia and stress-related sleep disturbances. The peptide's unique structure distinguishes it from other known peptide families, highlighting its exploratory status in neuroprotection.

SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide currently under investigation for its therapeutic potential in mitochondrial diseases and age-related dysfunctions. Developed by Stealth BioTherapeutics, it has been evaluated in several Phase I–III clinical trials, including the TAZPOWER trial focused on Barth syndrome. The peptide's unique mechanism of action and its ability to concentrate in the mitochondria underscore its promise in neuroprotection and metabolic health.

Humanin is a mitochondria-derived peptide composed of 21-24 amino acids, encoded by the MT-RNR2 gene. Discovered in 2001, it has garnered attention for its neuroprotective properties, particularly in the context of Alzheimer's disease. Research suggests that circulating levels of humanin decline with age, correlating with longevity in centenarian studies. Its broad spectrum of cytoprotective, anti-inflammatory, and metabolic effects positions it as a significant player in neuroprotection and metabolic health.

Cerebrolysin is a peptide complex derived from porcine brain proteins, consisting of low-molecular-weight neuropeptides and free amino acids. Its ability to cross the blood-brain barrier has led to its investigation in various neurological conditions, including stroke recovery. While some studies indicate potential benefits, a 2023 Cochrane review highlights the need for further evidence, as it found no clear mortality benefit associated with cerebrolysin treatment.

ARA-290, or cibinetide, is an 11-amino-acid synthetic peptide derived from erythropoietin (EPO). Unlike traditional EPO, which stimulates red blood cell production, ARA-290 selectively activates the innate repair receptor (IRR), making it a promising candidate for treating neuropathic pain and tissue repair. It has received FDA Orphan Drug Designation for sarcoidosis-associated small fiber neuropathy, and multiple Phase II clinical trials have demonstrated its efficacy in improving neuropathic pain and promoting nerve regeneration.

Adamax is a synthetic derivative of Semax, designed to enhance blood-brain barrier penetration and extend its half-life. This compound retains the core pharmacophore of Semax while incorporating an adamantane moiety, which is theorized to increase its potency in promoting neurotrophic factors such as BDNF. Currently, all evidence supporting Adamax is preclinical, with no human clinical trials published, thus its therapeutic potential remains to be fully validated.

Neuroxelin is a synthetic neuroprotective peptide that is hypothesized to modulate NMDA receptor activity while downregulating excessive microglial activation. The proposed mechanism suggests that Neuroxelin may protect neurons from excitotoxic damage and promote synaptic plasticity. However, it is important to note that the current evidence for Neuroxelin is primarily derived from vendor literature and preliminary in vitro studies, with no peer-reviewed clinical trials available. This limitation raises questions about the robustness of the findings and the generalizability of its effects. The peptide is part of a broader category of novel neuropeptides marketed to the biohacking community, yet its scientific validation remains insufficient.

FGL(S) is a synthetic peptide derived from the neural cell adhesion molecule (NCAM) that has garnered attention for its potential neuroprotective properties. This peptide activates the fibroblast growth factor receptor (FGFR) directly, promoting neurite outgrowth, neuronal survival, and synaptic plasticity in various preclinical models. The peptide's ability to enhance neuronal health makes it a subject of interest in neuroprotective research, although its clinical implications remain untested in human trials.

N-Acetyl Selank Amidate is a modified variant of Selank, designed for improved metabolic stability through N-acetylation and C-amidation. While the base form of Selank has received approval in Russia for the treatment of anxiety and cognitive disorders, N-Acetyl Selank Amidate has gained popularity within the research peptide community, particularly for intranasal applications. Despite its emerging use, robust clinical data supporting its efficacy and safety in humans are still lacking.

P21 is a synthetic peptide derived from the active region of Ciliary Neurotrophic Factor (CNTF), designed to promote neurogenesis in the hippocampus while avoiding the immunogenic side effects associated with full-length CNTF. Preclinical studies, particularly in mouse models of Alzheimer's disease, have indicated that P21 may improve spatial memory and stimulate neurogenesis. Although P21 has gained traction in the nootropics community, it lacks clinical data from human trials, limiting its applicability and understanding in broader contexts.